Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer

MLA

Xuejun Yu, et al. “Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.” Cancer Management and Research, Sept. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....cc4ed6bb357aa1ccb98ddff60ab7bbc5&authtype=sso&custid=ns315887.

APA

Xuejun Yu, Jisheng Li, Ling Peng, Li Li, Beibei Chen, Ying Sun, & Shuguang Li. (2021). Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer. Cancer Management and Research.

Chicago

Xuejun Yu, Jisheng Li, Ling Peng, Li Li, Beibei Chen, Ying Sun, and Shuguang Li. 2021. “Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.” Cancer Management and Research, September. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....cc4ed6bb357aa1ccb98ddff60ab7bbc5&authtype=sso&custid=ns315887.